Biotie: Selincro enters the market in France
September 19, 2014 04:43 ET
|
Biotie Therapies Oyj
TURKU, Finland, Sept. 19, 2014 (GLOBE NEWSWIRE) --
Biotie: Selincro enters the market in France
Biotie today announced that its partner H. Lundbeck A/S (Lundbeck) has brought...
Biotie: Selincro enters the market in Germany
August 29, 2014 02:11 ET
|
Biotie Therapies Oyj
TURKU, Finland, Aug. 29, 2014 (GLOBE NEWSWIRE) -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Germany. According to the terms of the license...
Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
July 24, 2014 08:28 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 24, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR...
Biotie: Selincro enters the market in Spain
July 22, 2014 02:22 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 22, 2014 (GLOBE NEWSWIRE) -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Spain. According to the terms of the license...
Biotie: Selincro receives positive draft guidance from UK's NICE
July 10, 2014 06:22 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 10, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology...
Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology
July 08, 2014 02:16 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) -- Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson's disease patients...
Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Disease Dementia
July 08, 2014 02:09 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies has signed a USD 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson's disease...
Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014
May 27, 2014 02:10 ET
|
Biotie Therapies Oyj
TURKU, Finland, May 27, 2014 (GLOBE NEWSWIRE) -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 27 May 2014 at 9.00 a.m.
Biotie:...
Biotie: Lundbeck and Otsuka announce partnership to develop and commercialize nalmefene in Japan
October 31, 2013 06:47 ET
|
Biotie Therapies Oyj
TURKU, Finland, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has expanded its existing alliance with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to...
Biotie: Selincro enters the market in Italy
September 26, 2013 02:39 ET
|
Biotie Therapies Oyj
TURKU, Sept. 26, 2013 (GLOBE NEWSWIRE) -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 September 2013 at 9.00 a.m.
Biotie: Selincro enters the market in Italy
Biotie today...